{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-25-000011","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.024483+00:00","generated_at":"2026-05-24T21:14:52.603017+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Intensity Therapeutics reports 2024 net loss of $16.3M; cash $2.6M; trial enrollment ongoing","bullets":["Net loss of $16.3M for FY2024 vs $10.5M in 2023; R&D expenses rose to $10.5M from $4.8M.","Cash and cash equivalents total $2.6M as of December 31, 2024.","INVINCIBLE-3 (Phase 3 sarcoma) has 32 sites contracted, 25 patients screened; enrollment expected by first half 2026.","INVINCIBLE-4 (Phase 2 TNBC) has 8 Swiss sites activated, several patients treated; enrollment expected end Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-25-000011","json":"https://secwatch.observer/filing/0001567264-25-000011.json","markdown":"https://secwatch.observer/filing/0001567264-25-000011.md","text":"https://secwatch.observer/filing/0001567264-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000011/0001567264-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000011/intensity-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:14:52.603017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}